Cargando…

A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients

BACKGROUND: The aim of this study was to propose a prognostic scoring system based on preoperative serum apolipoprotein A-1 and C-reactive protein (ApoA-1 and CRP, AC score) levels and to evaluate the prognostic value of these markers in patients with hepatocellular carcinoma (HCC). METHODS: In all,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Minjie, Wang, Xueping, Sheng, Hui, Liu, Yijun, Zhang, Lin, Dai, Shuqin, Chi, Pei-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260712/
https://www.ncbi.nlm.nih.gov/pubmed/30486825
http://dx.doi.org/10.1186/s12885-018-5028-8
_version_ 1783374854675759104
author Mao, Minjie
Wang, Xueping
Sheng, Hui
Liu, Yijun
Zhang, Lin
Dai, Shuqin
Chi, Pei-dong
author_facet Mao, Minjie
Wang, Xueping
Sheng, Hui
Liu, Yijun
Zhang, Lin
Dai, Shuqin
Chi, Pei-dong
author_sort Mao, Minjie
collection PubMed
description BACKGROUND: The aim of this study was to propose a prognostic scoring system based on preoperative serum apolipoprotein A-1 and C-reactive protein (ApoA-1 and CRP, AC score) levels and to evaluate the prognostic value of these markers in patients with hepatocellular carcinoma (HCC). METHODS: In all, 539 consecutive cases diagnosed with HCC from 2009 to 2012 at Sun Yat-sen University Cancer Center were analysed. The characteristics and levels of pretreatment lipids (ApoA-1, apolipoprotein B (Apo-B), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs)) and CRP were reviewed and determined by univariate and multivariate Cox hazard models. Then, the AC score was proposed, which combines two independent risk factors (ApoA-1 and CRP). RESULTS: The optimal cut-off points in our study were determined according to established reference ranges. Patients with decreased ApoA-1 levels (< 1.090 g/L) and increased CRP levels (≥3.00 mg/L) exhibited a significantly poor overall survival (OS) and disease-free survival (DFS). The AC score was calculated as follows: patients with decreased ApoA-1 and elevated CRP were given a score of 3, patients with only one of these abnormalities were given a score of 2, and those with no abnormalities were given a score of 1. Patients with a higher AC score showed more progressive disease and a poorer prognosis. This was observed not only in the entire cohort (for OS, P < 0.001; for DFS, P < 0.001) but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). The discriminatory ability of the AC score in HCC was assessed according to the AUC values. The AUC value of the AC score (AUC: 0.676, 95% CI: 0.629–0.723, P < 0.001) was higher than that of AFP. In addition, the combination of the AFP and AC scores (AUC: 0.700, 95% CI: 0.655–0.745, P < 0.001) was superior to the AFP and AC scores alone. CONCLUSIONS: The AC score is a significant valuable predictor of OS and DFS and could more accurately differentiate the prognosis of HCC patients. As this study is a retrospective analysis, the value of the AC score should be validated in large prospective trials.
format Online
Article
Text
id pubmed-6260712
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62607122018-11-30 A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients Mao, Minjie Wang, Xueping Sheng, Hui Liu, Yijun Zhang, Lin Dai, Shuqin Chi, Pei-dong BMC Cancer Research Article BACKGROUND: The aim of this study was to propose a prognostic scoring system based on preoperative serum apolipoprotein A-1 and C-reactive protein (ApoA-1 and CRP, AC score) levels and to evaluate the prognostic value of these markers in patients with hepatocellular carcinoma (HCC). METHODS: In all, 539 consecutive cases diagnosed with HCC from 2009 to 2012 at Sun Yat-sen University Cancer Center were analysed. The characteristics and levels of pretreatment lipids (ApoA-1, apolipoprotein B (Apo-B), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs)) and CRP were reviewed and determined by univariate and multivariate Cox hazard models. Then, the AC score was proposed, which combines two independent risk factors (ApoA-1 and CRP). RESULTS: The optimal cut-off points in our study were determined according to established reference ranges. Patients with decreased ApoA-1 levels (< 1.090 g/L) and increased CRP levels (≥3.00 mg/L) exhibited a significantly poor overall survival (OS) and disease-free survival (DFS). The AC score was calculated as follows: patients with decreased ApoA-1 and elevated CRP were given a score of 3, patients with only one of these abnormalities were given a score of 2, and those with no abnormalities were given a score of 1. Patients with a higher AC score showed more progressive disease and a poorer prognosis. This was observed not only in the entire cohort (for OS, P < 0.001; for DFS, P < 0.001) but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). The discriminatory ability of the AC score in HCC was assessed according to the AUC values. The AUC value of the AC score (AUC: 0.676, 95% CI: 0.629–0.723, P < 0.001) was higher than that of AFP. In addition, the combination of the AFP and AC scores (AUC: 0.700, 95% CI: 0.655–0.745, P < 0.001) was superior to the AFP and AC scores alone. CONCLUSIONS: The AC score is a significant valuable predictor of OS and DFS and could more accurately differentiate the prognosis of HCC patients. As this study is a retrospective analysis, the value of the AC score should be validated in large prospective trials. BioMed Central 2018-11-28 /pmc/articles/PMC6260712/ /pubmed/30486825 http://dx.doi.org/10.1186/s12885-018-5028-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mao, Minjie
Wang, Xueping
Sheng, Hui
Liu, Yijun
Zhang, Lin
Dai, Shuqin
Chi, Pei-dong
A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title_full A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title_fullStr A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title_full_unstemmed A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title_short A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
title_sort novel score based on serum apolipoprotein a-1 and c-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260712/
https://www.ncbi.nlm.nih.gov/pubmed/30486825
http://dx.doi.org/10.1186/s12885-018-5028-8
work_keys_str_mv AT maominjie anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT wangxueping anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT shenghui anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT liuyijun anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT zhanglin anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT daishuqin anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT chipeidong anovelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT maominjie novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT wangxueping novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT shenghui novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT liuyijun novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT zhanglin novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT daishuqin novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients
AT chipeidong novelscorebasedonserumapolipoproteina1andcreactiveproteinisaprognosticbiomarkerinhepatocellularcarcinomapatients